633 related articles for article (PubMed ID: 25698453)
1. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
[TBL] [Abstract][Full Text] [Related]
2. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
3. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
4. Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T - a case report.
Welsner M; Straßburg S; Taube C; Sutharsan S
BMC Pulm Med; 2019 Apr; 19(1):76. PubMed ID: 30975115
[TBL] [Abstract][Full Text] [Related]
5. A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor.
Char JE; Wolfe MH; Cho HJ; Park IH; Jeong JH; Frisbee E; Dunn C; Davies Z; Milla C; Moss RB; Thomas EA; Wine JJ
PLoS One; 2014; 9(2):e88564. PubMed ID: 24520399
[TBL] [Abstract][Full Text] [Related]
6. Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation.
Yousef S; Solomon GM; Brody A; Rowe SM; Colin AA
Chest; 2015 Mar; 147(3):e79-e82. PubMed ID: 25732475
[TBL] [Abstract][Full Text] [Related]
7. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
8. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
9. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
Kotha K; Clancy JP
Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
[TBL] [Abstract][Full Text] [Related]
10. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
Flume PA; Liou TG; Borowitz DS; Li H; Yen K; Ordoñez CL; Geller DE;
Chest; 2012 Sep; 142(3):718-724. PubMed ID: 22383668
[TBL] [Abstract][Full Text] [Related]
11. The Role of Ivacaftor in Severe Cystic Fibrosis in a Patient With the R117H Mutation.
Ronan NJ; Fleming C; O'Callaghan G; Maher MM; Murphy DM; Plant BJ
Chest; 2015 Sep; 148(3):e72-e75. PubMed ID: 26324139
[TBL] [Abstract][Full Text] [Related]
12. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599
[TBL] [Abstract][Full Text] [Related]
13. Ivacaftor potentiation of multiple CFTR channels with gating mutations.
Yu H; Burton B; Huang CJ; Worley J; Cao D; Johnson JP; Urrutia A; Joubran J; Seepersaud S; Sussky K; Hoffman BJ; Van Goor F
J Cyst Fibros; 2012 May; 11(3):237-45. PubMed ID: 22293084
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
15. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
16. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW
Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840
[TBL] [Abstract][Full Text] [Related]
17. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
[TBL] [Abstract][Full Text] [Related]
18. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.
Guimbellot JS; Baines A; Paynter A; Heltshe SL; VanDalfsen J; Jain M; Rowe SM; Sagel SD;
J Cyst Fibros; 2021 Mar; 20(2):213-219. PubMed ID: 33249004
[TBL] [Abstract][Full Text] [Related]
19. The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report.
Johns JD; Rowe SM
BMC Gastroenterol; 2019 Jul; 19(1):123. PubMed ID: 31296159
[TBL] [Abstract][Full Text] [Related]
20. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]